A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in Portugal
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to understand how the participants with high-risk non-muscle invasive bladder cancer are diagnosed, treated, and cared for in regular clinical practice in Portugal. HR-NMIBC is an early-stage bladder cancer that is limited to the inner lining of bladder but has a considerable high chance of cancer coming back or worsening.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznanie raka pęcherza moczowego w okresie od stycznia 2016 do grudnia 2020
- •Guz na wczesnym etapie bez przerzutów odległych, o wysokim ryzyku (określone typy)
- •Okres obserwacji co najmniej 5 lat (chyba że pacjent zmarł wcześniej)
✗ Disqualifies
- •Guz zaawansowany lub z przerzutami do innych narządów
- •Wcześniejsza całkowita usunięcia pęcherza moczowego
- •Udział w innym badaniu klinicznym podczas okresu obserwacji
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 25, 2026
- Sex
- No restrictions
Locations (1)
Ipo Lisboa
Lisbon, Portugal
Trial contact
Study Contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/26/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.